TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06707805

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Physical therapy
Description: Conventional treatment protocol including moist Heating pad for low back pain for 15 minutes. TENS for pain for 10 minutes. Stretchings of tight muscles would be 1 set of 5-7 reps with 5 sec. hold 3 times a week. Strengthing of weak muscles would be 2-3 times a weak with 10-15 reps.Stretching protocol will be followed for Iliopsoas and erector spinae muscles. Strengthening protocol will be followed for weak abdominals and Gluteus maximus muscles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lumber SNAGS
Description: : Lumber mobilizations with conventional treatment protocol.~* Lumber Mulligan(SNAGs) technique~* Technique applied at L4-L5, L5-S1 level.~* Techniques applied for flexion ,extension, side bending and rotation 6 to 8 cycles per session
Study: NCT06706947

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphaticovenous Anastomosis
Description: Lymphaticovenous Anastomosis (LVA) is an emerging super-microsurgical procedure pioneered by Professor Xie Qingping and his team, a group of Chinese microsurgery experts. This technique has been published in the official journal of the American Society of Plastic Surgeons (ASPS), confirming its effectiveness in improving the drainage function of the brain and reducing lymphatic pressure in deep brain tissues. By establishing an anastomosis between lymphatic vessels and veins in the neck, the surgery enhances the drainage of cerebrospinal fluid, alleviating the accumulation of toxins and waste within the brain, thereby easing the symptoms of Alzheimer's disease. Due to its significant contribution to the field of microsurgery, this innovative surgery has been selected as one of the Top Seven Advances in Microsurgery for 2022.
Study: NCT04707846

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright Blue Light Commercial AYO Light Therapy Device
Description: AYO light therapy glasses are a commercially available device which have 4 Light-emitting diodes (LEDs) with a dominant wavelength of approximately 470nm ± 2nm and typical irradiance (100% intensity) of approximately 250 µW/cm². AYO bright light glasses are classified as exempt for photo-biological risk based on the international standard and conformity assessment for photo-biological safety of lamps (IEC 62471).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dim Blue Light Commercial AYO Light Therapy Device
Description: AYO light therapy glasses were made available to the research team by the vendor. The device has 4 Light-emitting diodes (LEDs) with a dominant wavelength of approximately 470nm ± 2nm and reduced irradiance (1% intensity) of approximately 250 µW/cm². AYO dim light glasses are classified as exempt for photo-biological risk based on the international standard and conformity assessment for photo-biological safety of lamps (IEC 62471).
Study: NCT06708767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contrast Media
Description: IV contrast media administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contrast Media
Description: IV contrast media administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contrast Media
Description: IV contrast media administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline
Study: NCT06708897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE 50-0134
Description: oral capsules QD
Study: NCT05717387

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: Participants in the TRE group will be instructed to eat during a window of 8 h/d (8 am to 4 pm).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The 5:2 diet
Description: Participants will be instructed to consume 500-600 kcal/d on fast days and eat ad libitum on feast days.
Study: NCT04654351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-667
Description: TAK-667 single SC administration
Study: NCT06043375

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Licorice Root Powder Capsule
Description: Fresh licorice root will be obtained from local market of Lahore. The root will be washed and dried at room temperature. Then it will be converted into powder using grinder. After sieving the ground powder, it will be filled in capsules. One capsule will contain 1000mg of powder. Participants in experimental group will be instructed to consume one capsule per day.
Study: NCT06251206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADL/Postoperative Instruction
Description: This is an education video which includes demonstration of simple ADL tasks that the participant can do at home after surgery. Handout includes the same information and a QR code to watch the video.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postoperative Instruction
Description: This is an education video that only includes the postoperative instructions. Handout includes the same information and a QR code to watch the video.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative Instruction
Description: This is an education video that only includes the postoperative instructions. Handout includes the same information and a QR code to watch the video.
Study: NCT05485727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Lokomat® Pro Hocoma USA & Conventional physical therapy
Description: Lokomat Consists of robotic gait orthosis and an advanced body weight support system, combined with a Treadmill. (used for gait training) and Conventional Physical Therapy
Study: NCT06708897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE 50-0134
Description: oral capsules QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE 50-0134
Description: oral capsules QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE 50-0134
Description: oral capsules QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE 50-0134
Description: oral capsules QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE 50-0134
Description: oral capsules QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE 50-0134
Description: oral capsules QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE 50-0134
Description: oral capsules QD
Study: NCT06708884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: exercise programme will be implemented via telerehabilitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: exercise programme will be implemented via face-to-face
Study: NCT06708650

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Combination of SFRT, PD-L1 inhibitor, and Anti-VEGF
Description: Patients received intravenous PD-1 inhibitor 200mg(Camrelizumab, Tislelizumab, or Sintilimab) plus oral Apatinib 250 mg or Lenvatinib 12mg (for bodyweight ≥60 kg) or 8 mg/kg (for bodyweight \<60 kg) daily, and additional SFRT for primary liver tumor. PD-1 inhibitor is administered for 2 years or until disease progression or intolerance. Anti-VEGFR is continued until disease progression or intolerance. SFRT implementation plan is as follows: The GTV consists of 2-5 sub-target volumes, which are cylindrical shapes with a diameter of 1.6cm, a height of 2cm, and an interval of 3-5cm. The total volume of the GTV is about 8-20cc, and the distance between the GTV and the OARs is greater than 2cm. The prescribed dosage for each course of radiotherapy is 24 Gy in 3 daily fractions (8Gy x 3F), with a 3-week interval between courses (Q3W). The total courses of radiotherapy shall not be less than 2 (depending on the efficacy and cumulative dose of OARs).
Study: NCT06695299

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: selected exercise program
Description: therapeutic ultrasound, Static neck exercise, balance exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: selected exercise program
Description: therapeutic ultrasound, Static neck exercise, balance exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesthetic and Visual Motor Imagery Training
Description: Kinesthetic and Visual Motor Imagery Training During kinesthetic imagery, the participants were asked to feel their body parts without any body motion. During visual imagery, the participants were asked to perform a visual presentation of the motion without any body motion.
Study: NCT06710743

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose solution Day 1, Day 8, and Day 15
Description: Glucodin powder diluted with water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food (cereal). Ten different cereals served once each
Description: Variety of cooked or flake cereal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food (cereal). Ten different cereals served once each
Description: Variety of cooked or flake cereal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food (cereal). Ten different cereals served once each
Description: Variety of cooked or flake cereal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food (cereal). Ten different cereals served once each
Description: Variety of cooked or flake cereal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food (cereal). Ten different cereals served once each
Description: Variety of cooked or flake cereal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food (cereal). Ten different cereals served once each
Description: Variety of cooked or flake cereal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food (cereal). Ten different cereals served once each
Description: Variety of cooked or flake cereal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food (cereal). Ten different cereals served once each
Description: Variety of cooked or flake cereal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food (cereal). Ten different cereals served once each
Description: Variety of cooked or flake cereal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food (cereal). Ten different cereals served once each
Description: Variety of cooked or flake cereal
Study: NCT06710678

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Study Break
Description: A 10-minute walking/upper extremity light movement indoor break from study session

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media Study Break
Description: Participants will engage in social media use/engagement during a 10-minute study session break
Study: NCT06707181

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: • The study will include 180 randomly selected patients who met inclusion criteria were randomized into four groups: silodosin 8 mg (Group A), tamsulosin 0.4 mg (Group B), silodosin 8 mg plus tadalaf
Description: • The study will include 180 randomly selected patients who met inclusion criteria were randomized into four groups: silodosin 8 mg (Group A), tamsulosin 0.4 mg (Group B), silodosin 8 mg plus tadalafil 5 mg (Group C) and tamsulosin 0.4 mg plus tadalafil 5 mg (Group D). Drugs are given for a maximal duration of 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: • The study will include 180 randomly selected patients who met inclusion criteria were randomized into four groups: silodosin 8 mg (Group A), tamsulosin 0.4 mg (Group B), silodosin 8 mg plus tadalaf
Description: • The study will include 180 randomly selected patients who met inclusion criteria were randomized into four groups: silodosin 8 mg (Group A), tamsulosin 0.4 mg (Group B), silodosin 8 mg plus tadalafil 5 mg (Group C) and tamsulosin 0.4 mg plus tadalafil 5 mg (Group D). Drugs are given for a maximal duration of 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: • The study will include 180 randomly selected patients who met inclusion criteria were randomized into four groups: silodosin 8 mg (Group A), tamsulosin 0.4 mg (Group B), silodosin 8 mg plus tadalaf
Description: • The study will include 180 randomly selected patients who met inclusion criteria were randomized into four groups: silodosin 8 mg (Group A), tamsulosin 0.4 mg (Group B), silodosin 8 mg plus tadalafil 5 mg (Group C) and tamsulosin 0.4 mg plus tadalafil 5 mg (Group D). Drugs are given for a maximal duration of 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: • The study will include 180 randomly selected patients who met inclusion criteria were randomized into four groups: silodosin 8 mg (Group A), tamsulosin 0.4 mg (Group B), silodosin 8 mg plus tadalaf
Description: • The study will include 180 randomly selected patients who met inclusion criteria were randomized into four groups: silodosin 8 mg (Group A), tamsulosin 0.4 mg (Group B), silodosin 8 mg plus tadalafil 5 mg (Group C) and tamsulosin 0.4 mg plus tadalafil 5 mg (Group D). Drugs are given for a maximal duration of 28 days.
Study: NCT06708273

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constraint induced movement therapy
Description: Constraint the sound side and encourage movement of the burned side

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positioning - stretching
Description: Position hand in functional hand position - stretching against deformity position

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positioning - stretching
Description: Position hand in functional hand position - stretching against deformity position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: constraint induced movement therapy
Description: constraining sound hand to enforce patient to use affected burned dominant hand
Study: NCT06726577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP04HN106
Description: During the treatment period, the experimental drug group received intravenous injections of 0.83mL/kg TP04HN106 each time; During the extension period, all subjects received intravenous injection of 0.83mL/kg TP04HN106.
Study: NCT05180045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LINKED-BP Program
Description: The intervention arm will include training on HBPM, Sphygmo BP telemonitoring app, and CHW visits for education and counseling on lifestyle modification. Patients will be trained to measure their BP in the morning and evening for 7 days. Patients enter data using Bluetooth device transmission or manual entry. Guidance is provided on accurate BP measurement. The app stores and securely relays data to the cloud. The primary care provider and CHW will be able to visualize the remotely transmitted data via the clinician portal. Other components of usual care at the practices may include dietary counseling, on-site clinical pharmacists, social workers, case managers as needed for BP follow up, and assistance with medications and appointments as needed. The intervention period for each study participant is 12 months.
Study: NCT05787574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emapalumab
Description: Emapalumab on Days -22 (22 days before the day of the stem cell transplant), -15, -8, and -1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine and Dexamethasone
Description: Fludarabine and dexamethasone for 5 days in a row on Days -22 through -18.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Participants in both groups will receive their standard-of-care stem cell transplant on Day 0.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Participants in both groups will receive their standard-of-care stem cell transplant on Day 0.
Study: NCT04758507

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: donor FMT
Description: This intervention is represented by the administration, in the recipients' gut, of donor microbiota through FMT

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo FMT
Description: This intervention is represented by the administration, in the recipients' gut, of a placebo through FMT
Study: NCT06085833

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nanomechanical Phenotype Test
Description: The ARTIDIS ART-1 device is an in-vitro diagnostic device based on Atomic Force Microscope (AFM) technology. The ART-1 device uses a probe to measure the nanomechanical phenotype of tissue components. ARTIDIS nanomechanical phenotype measurements are performed on fresh tissue after it is collected via biopsy or resection.
Study: NCT06058637

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eye screening
Description: Nurse-assisted eye-screening will take place with the Easee app, which is implemented on the tablet or laptop of the community nurse. The nurse's smartphone will function as a remote control by which he/she submits input to a computer screen that displays the test. If the participant can do the test by him or herself, the nurse will merely supervise to ensure correct application. Standard audio instructions guide the nurse and participant through the test. The test will start with triage questions, which are used to set up a correct referral. During the test, both eyes are tested consecutively, covering one eye at a time. The participant will wear his/her spectacles, if present. The participant is presented a sequence of optotypes (i.e. tumbling-E and triangle-circle optotypes) that the participant must correctly identify, in addition to various grate sizes, both near and at a distance. The Amsler grid test is performed to detect any macular problems.
Study: NCT06577857

Intervention type: DEVICE
Intervention: Inferonasal Minimally Invasive Micro Sclerostomy
Description: The Inferonasal MIMS® procedure uses the proprietary MIMS® device, which creates a sclerostomy in the inferonasal quadrant of the eye.
Study: NCT05876585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg ampoule
Description: Study drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide 10 mg ampoule
Description: Comparator drug
Study: NCT04761393

Intervention type: PROCEDURE
Intervention: Hyperpolarized 129Xe (Xenon) diffusion-weighted MRI
Description: Participants will inhale a one litre gas mixture containing hyperpolarized 129Xe mixed with nitrogen (N2) or helium (4He) from a one litre dose bag. Breath-hold will be up to 16 seconds

Intervention type: PROCEDURE
Intervention: Hyperpolarized 129Xe (Xenon) diffusion-weighted MRI
Description: Participants will inhale a one litre gas mixture containing hyperpolarized 129Xe mixed with nitrogen (N2) or helium (4He) from a one litre dose bag. Breath-hold will be up to 16 seconds
Study: NCT06726577

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The placebo group received intravenous injections of 0.83mL/kg of saline each time. In the experiment, all subjects received Liraglutide tablets as the standard baseline treatment.
Study: NCT06736899

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orbital Atherectomy System Treatment
Description: Percutaneous coronary intervention of a calcified bifurcation coronary lesion with balloon angioplasty followed by drug eluting stent. Selection of balloon type is at operator´s discretion. Baseline and post dilation OCT will be performed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon System Treatment
Description: Percutaneous coronary intervention of a calcified bifurcation coronary lesion with Orbital Atherectomy followed by drug eluting stent. Baseline and post dilation OCT will be performed.
Study: NCT06742320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma education
Description: There are very few studies examining the asthma knowledge level, quality of life and asthma control of children in Turkey.
Study: NCT06744400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grafalon® administered during 5 consecutive days at 2 mg/kg/j
Description: This de-escalation study was planned to investigate 3 doses level of Grafalon® administered during 5 consecutive days, i.e.:~Group 3 : 2 mg/kg/j, Group 2 : 1 mg/kg/j, Group 1 : 0,5 mg/kg/j.~Group 3 receives treatment in accordance with health recommendations as part of prophylactic treatment for acute rejection after allogeneic solid organ transplantation, at the minimum dose, i.e., 2 to 5 mg/kg/day for 5 to 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grafalon® administered during 5 consecutive days at 1 mg/kg/j
Description: This de-escalation study was planned to investigate 3 doses level of Grafalon® administered during 5 consecutive days, i.e.:~Group 3 : 2 mg/kg/j, Group 2 : 1 mg/kg/j, Group 1 : 0,5 mg/kg/j.~Group 2 receive treatment at lower doses than the recommended dose for the same duration (5 days). Treatment begins on the day of transplantation immediately before the procedure at induction of sedation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grafalon® administered during 5 consecutive days at 0,5 mg/kg/j
Description: This de-escalation study was planned to investigate 3 doses level of Grafalon® administered during 5 consecutive days, i.e.:~Group 3 : 2 mg/kg/j, Group 2 : 1 mg/kg/j, Group 1 : 0,5 mg/kg/j.~Group 1 receive treatment at lower doses than the recommended dose for the same duration (5 days). Treatment begins on the day of transplantation immediately before the procedure at induction of sedation
Study: NCT06737016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Children will be maintained on an oral dose of Tamsulosin 0.1 mg once daily (in children aged less than 2 years old) and 0.2 mg once daily (≥2 years old).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin
Description: Children will be maintained on an oral dose of Oxybutynin 0.2 mg/kg 2 times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Description: Children will be maintained on an oral dose of Oxybutynin 0.2 mg/kg 2 times daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole (TMP/SMZ)
Description: Children will be maintained on an oral prophylactic dose of Trimethoprim/sulfamethoxazole 2 mg/kg single dose at night.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (TMP/SMZ)
Description: Children will be maintained on an oral prophylactic dose of Trimethoprim/sulfamethoxazole 2 mg/kg single dose at night.
Study: NCT06744452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: harmony
Description: Use of the app-based digital self-help intervention harmony over a 12-week-period. The app was designed for stress management and the preventive promotion of mental health. Harmony provides users with access to a wide range of psychological self-help content, including video episodes, audio sessions, texts, and downloadable materials. Utilizing artificial intelligence, Harmony offers personalized content suggestions tailored to the user's individual situation and preferences, ensuring the content remains relevant and updated. Content is delivered through a combination of psychoeducation, guided exercises, relaxation techniques, meditations, practical tasks, self-reflection activities, and everyday application tasks.